Navigating the strategic path to enantiopurity

A closer look at how controlled crystallisation and complementary approaches can be used to efficiently separate and purify chiral molecules.

Changing Faces: Boards of Directors and Advisory Boards – Ap...

Boardrooms and advisory panels across biotech, pharma, digital health, and life sciences suppliers saw a wave of high‑profile additions in April.

Simplification, standardisation & AI-enabled industry: Veeva...

Focused on innovating together, and together advancing industry, the Veeva R&D Summit this year highlighted an intention on one, AI-enabled cloud.

IQVIA on reducing complexity and workload for clinical trial...

Changing Faces: Pharma and biotech, April 2026

April didn’t see too much activity at the big pharmas, but saw plenty of executive movement at small and midsized biotechs.

Why UCB bet a billion dollars on cell therapy for epilepsy

UCB's chief science officer spoke to pharmaphorum about why Neurona's in-development cell therapy could be a game changer for epilepsy treatment.